Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in EUR (TTM)1.15bn
- Net income in EUR-275.83m
- Incorporated2008
- Employees1.15k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recordati Industria Chmc Frmctc SpA | 2.08bn | 389.21m | 10.45bn | 4.46k | 26.55 | 6.11 | 19.44 | 5.02 | 1.88 | 1.88 | 10.08 | 8.19 | 0.5075 | 1.59 | 5.16 | 467,414.40 | 9.48 | 11.67 | 12.40 | 15.02 | 68.32 | 70.43 | 18.69 | 21.45 | 0.795 | 8.34 | 0.5175 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Eurofins Scientific SE | 6.51bn | 516.50m | 10.97bn | 61.80k | 21.78 | 2.15 | 9.68 | 1.68 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
| BioMerieux SA | 3.67bn | 357.60m | 11.92bn | 14.65k | 33.46 | 3.17 | 19.34 | 3.24 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sandoz Group AG | -102.14bn | -102.14bn | 13.52bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Genmab A/S | 2.21bn | 583.50m | 17.48bn | 2.20k | 29.86 | 4.08 | -- | 7.92 | 66.05 | 66.05 | 249.95 | 483.85 | 0.5037 | -- | 3.09 | 7,474,592.00 | 13.31 | 17.43 | 14.25 | 18.59 | 55.82 | -- | 26.42 | 35.87 | 13.32 | -- | 0.0238 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| argenx SE | 1.15bn | -275.83m | 20.80bn | 1.15k | -- | 5.41 | -- | 18.14 | -4.81 | -4.81 | 20.11 | 64.71 | 0.3195 | 0.4373 | 3.72 | 998,614.30 | -7.69 | -17.65 | -8.49 | -19.79 | 90.39 | -- | -24.06 | -97.72 | 9.01 | -- | 0.0049 | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| UCB SA | 5.25bn | 343.00m | 23.50bn | 9.08k | 68.62 | 2.55 | 22.72 | 4.47 | 1.76 | 1.76 | 26.91 | 47.30 | 0.3345 | 1.76 | 4.63 | 578,223.10 | 2.18 | 5.03 | 2.67 | 6.28 | 67.50 | 72.21 | 6.53 | 12.66 | 0.9224 | 3.14 | 0.2529 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
| Bayer AG | 47.64bn | -2.94bn | 26.50bn | 99.72k | -- | 0.8047 | 3.55 | 0.5562 | -2.99 | -2.99 | 48.49 | 33.52 | 0.3951 | 1.43 | 4.85 | 477,693.20 | -2.44 | -1.79 | -3.34 | -2.38 | 58.54 | 59.02 | -6.18 | -4.80 | 0.8015 | 3.40 | 0.5764 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -47.66 |
| Holder | Shares | % Held |
|---|---|---|
| Schroder Investment Management Ltd.as of 31 Jan 2024 | 2.66m | 4.48% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.09m | 3.53% |
| Federated Global Investment Management Corp.as of 18 Oct 2022 | 1.65m | 2.78% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.63m | 2.76% |
| Wellington Management Co. LLPas of 26 Jan 2024 | 1.52m | 2.56% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.10m | 1.86% |
| Bellevue Asset Management AGas of 30 Sep 2023 | 859.78k | 1.45% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 483.40k | 0.82% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 413.57k | 0.70% |
| Polar Capital LLPas of 29 Feb 2024 | 379.01k | 0.64% |
